LFWD Quote, Financials, Valuation and Earnings

Twist Bioscience Corp. has a net margin of -51.17% compared to Lifeward Ltd.'s net margin of -27.41%. Lifeward Ltd.'s return on equity of -150.63% beat Twist Bioscience Corp.'s return on equity of -16.74%.

Lifeward Ltd. has a consensus price target of $5.17, signalling upside risk potential of 638.1%. On the other hand Twist Bioscience Corp. has an analysts' consensus of $35.63 which suggests that it could grow by 8.58%. Given that Lifeward Ltd. has higher upside potential than Twist Bioscience Corp., analysts believe Lifeward Ltd. is more attractive than Twist Bioscience Corp..

Lifeward Ltd. has a beta of 0.010, which suggesting that the stock is 99.011% less volatile than S&P 500. In comparison Twist Bioscience Corp. has a beta of 2.242, suggesting its more volatile than the S&P 500 by 124.157%.

Lifeward Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Twist Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifeward Ltd. pays -- of its earnings as a dividend. Twist Bioscience Corp. pays out -- of its earnings as a dividend.

Lifeward Ltd. quarterly revenues are $6.2M, which are smaller than Twist Bioscience Corp. quarterly revenues of $99M. Lifeward Ltd.'s net income of -$3.2M is higher than Twist Bioscience Corp.'s net income of -$27.1M. Notably, Lifeward Ltd.'s price-to-earnings ratio is -- while Twist Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifeward Ltd. is 0.33x versus 5.24x for Twist Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -51.17% compared to Lifeward Ltd.'s net margin of -862.39%. Lifeward Ltd.'s return on equity of -150.63% beat VolitionRX Ltd.'s return on equity of --.

Lifeward Ltd. has a consensus price target of $5.17, signalling upside risk potential of 638.1%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.60 which suggests that it could grow by 734.94%. Given that VolitionRX Ltd. has higher upside potential than Lifeward Ltd., analysts believe VolitionRX Ltd. is more attractive than Lifeward Ltd..

Lifeward Ltd. has a beta of 0.010, which suggesting that the stock is 99.011% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Lifeward Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifeward Ltd. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Lifeward Ltd. quarterly revenues are $6.2M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Lifeward Ltd.'s net income of -$3.2M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Lifeward Ltd.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifeward Ltd. is 0.33x versus 21.34x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services, Inc. has a net margin of -51.17% compared to Lifeward Ltd.'s net margin of 17.41%. Lifeward Ltd.'s return on equity of -150.63% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.

Lifeward Ltd. has a consensus price target of $5.17, signalling upside risk potential of 638.1%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $346.07 which suggests that it could grow by 22.82%. Given that Lifeward Ltd. has higher upside potential than West Pharmaceutical Services, Inc., analysts believe Lifeward Ltd. is more attractive than West Pharmaceutical Services, Inc..

Lifeward Ltd. has a beta of 0.010, which suggesting that the stock is 99.011% less volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.166, suggesting its more volatile than the S&P 500 by 16.617%.

Lifeward Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services, Inc. offers a yield of 0.3% to investors and pays a quarterly dividend of $0.22 per share. Lifeward Ltd. pays -- of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Lifeward Ltd. quarterly revenues are $6.2M, which are smaller than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. Lifeward Ltd.'s net income of -$3.2M is lower than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, Lifeward Ltd.'s price-to-earnings ratio is -- while West Pharmaceutical Services, Inc.'s PE ratio is 41.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifeward Ltd. is 0.33x versus 6.80x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -51.17% compared to Lifeward Ltd.'s net margin of 3.93%. Lifeward Ltd.'s return on equity of -150.63% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Lifeward Ltd. has a consensus price target of $5.17, signalling upside risk potential of 638.1%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 145.78%. Given that Lifeward Ltd. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Lifeward Ltd. is more attractive than Xtant Medical Holdings, Inc..

Lifeward Ltd. has a beta of 0.010, which suggesting that the stock is 99.011% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Lifeward Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifeward Ltd. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Lifeward Ltd. quarterly revenues are $6.2M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Lifeward Ltd.'s net income of -$3.2M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Lifeward Ltd.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 59.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifeward Ltd. is 0.33x versus 0.67x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.